The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy.
CAR-T cell failures
Diffuse large B cell lymphoma
Journal
Clinical lymphoma, myeloma & leukemia
ISSN: 2152-2669
Titre abrégé: Clin Lymphoma Myeloma Leuk
Pays: United States
ID NLM: 101525386
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
21
09
2021
accepted:
05
11
2021
pubmed:
18
1
2022
medline:
28
4
2022
entrez:
17
1
2022
Statut:
ppublish
Résumé
Chimeric antigen receptor T (CAR-T) cells targeting CD19 result in durable responses in approximately 40% of DLBCL patients. Loncastuximab tesirine, an antibody drug conjugate targeting CD19 with a pyrrolobenzodiazepine payload, has activity against DLBCL. We evaluated the outcomes of 13 DLBCL patients relapsed after CAR-T cells treated with loncastuximab in the LOTIS-2 trial. Six patients (46%) had responses to loncastuximab (CR, n = 2). Median OS, PFS and duration of response after loncastuximab were 8.2, 1.4 and 8 months, respectively. Loncastuximab can achieve responses in patients progressing after CAR-T cells. Sequencing CD19-targeting therapies is possible in cases without CD19 loss.
Identifiants
pubmed: 35034868
pii: S2152-2650(21)02437-X
doi: 10.1016/j.clml.2021.11.005
pii:
doi:
Substances chimiques
Antigens, CD19
0
Antineoplastic Agents
0
Immunoconjugates
0
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e335-e339Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure PFC reports research funding from ADC Therapeutics; grants Genentech. Consulting: ADC Therapeutics, Kite Pharmaceuticals, Verastem, Seattle Genetics, Amgen TG Therapeutics. Speaker's bureau: Celgene KMA reports research funding from ADC Therapeutics. Consulting from ADC Therapeutics, Celgene, Gilead, Takeda, Roche and Beigene. Support by the University College London (UCL)/UCL Hospitals (UCLH) Biomedical Research Unit. ER reports research funding from ADC Therapeutics. WA reports research support Nurix Therapeutics. Consulting: ADC Therapeutics, Nurix, Kymera. ML reports research funding from ADC Therapeutics, BMS, Curis. Consulting: Kite, Janssen, Karyopharm, Astra-Zeneca, Acrotech, BeiGene, Legend, ADC Therapeutics, Spectrum, Morphosys, Daiichi Sankyo, Myeloid Therapeutics, Kyowa Kirin. JMZ reports research funding from ADC Therapeutics. Consulting: Seattle Genetics, Kyowa Kirin, Verastem, Secura Bio, Legend Biotech, Ono Therapeutics. MS reports research funding from ADC Therapeutics, Partner therapeutics. Advisory Amgen, Seattle genetics. Speaker's Bureau: Amgen, Celgene. BSK reports research funding from ADC Therapeutics. Consulting: ADC Therapeutics. MH reports Research Support/Funding: Takeda Pharmaceutical Company; Astellas Pharma. Consulting/advisory board: Incyte Corporation; ADC Therapeutics; Celgene Corporation; Pharmacyclics, Magenta Therapeutics, Omeros, AbGenomics, Verastem, TeneoBio. Speaker's Bureau: Sanofi Genzyme, AstraZeneca, BeiGene.